These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7522353)

  • 1. Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia.
    Peckham D; Crouch S; Humphreys H; Lobo B; Tse A; Knox AJ
    Thorax; 1994 Aug; 49(8):803-7. PubMed ID: 7522353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary function, serum markers of inflammation, and IgG antibodies to core lipopolysaccharide of Burkholderia cepacia in adults with cystic fibrosis, following colonization with Burkholderia cepacia.
    Hendry J; Nixon L; Dodd M; Elborn JS; Govan J; Shale DJ; Webb AK
    Pediatr Pulmonol; 2000 Jan; 29(1):8-10. PubMed ID: 10613780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia.
    Taylor RF; Gaya H; Hodson ME
    J Antimicrob Chemother; 1992 Mar; 29(3):341-4. PubMed ID: 1375595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory markers in cystic fibrosis.
    Rayner RJ; Wiseman MS; Cordon SM; Norman D; Hiller EJ; Shale DJ
    Respir Med; 1991 Mar; 85(2):139-45. PubMed ID: 1887131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa.
    Jones AM; Martin L; Bright-Thomas RJ; Dodd ME; McDowell A; Moffitt KL; Elborn JS; Webb AK
    Eur Respir J; 2003 Sep; 22(3):503-6. PubMed ID: 14516142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
    Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
    J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a PCR probe test for identifying Pseudomonas aeruginosa and Pseudomonas (Burkholderia) cepacia.
    O'Callaghan EM; Tanner MS; Boulnois GJ
    J Clin Pathol; 1994 Mar; 47(3):222-6. PubMed ID: 7512994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis.
    Elborn JS; Cordon SM; Shale DJ
    Pediatr Pulmonol; 1993 May; 15(5):287-91. PubMed ID: 8327287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.
    Muhdi K; Edenborough FP; Gumery L; O'Hickey S; Smith EG; Smith DL; Stableforth DE
    Thorax; 1996 Apr; 51(4):374-7. PubMed ID: 8733488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak.
    Whiteford ML; Wilkinson JD; McColl JH; Conlon FM; Michie JR; Evans TJ; Paton JY
    Thorax; 1995 Nov; 50(11):1194-8. PubMed ID: 8553277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis.
    Lekkas A; Gyi KM; Hodson ME
    J Cyst Fibros; 2006 May; 5(2):121-4. PubMed ID: 16650744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa.
    Hendry J; Elborn JS; Nixon L; Shale DJ; Webb AK
    Eur Respir J; 1999 Aug; 14(2):435-8. PubMed ID: 10515426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiology of lung infection in cystic fibrosis.
    Govan JR; Nelson JW
    Br Med Bull; 1992 Oct; 48(4):912-30. PubMed ID: 1281036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temocillin in cystic fibrosis: a retrospective pilot study.
    Kent L; Bradley JM; France M; Döring G; Carryn S; Bradbury I; Rendall J; Jones A; Elborn JS
    J Cyst Fibros; 2008 Nov; 7(6):551-4. PubMed ID: 18706868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.
    Gladman G; Connor PJ; Williams RF; David TJ
    Arch Dis Child; 1992 Feb; 67(2):192-5. PubMed ID: 1371914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating immunoreactive interleukin-6 in cystic fibrosis.
    Nixon LS; Yung B; Bell SC; Elborn JS; Shale DJ
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1764-9. PubMed ID: 9620903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis.
    Snell GI; de Hoyos A; Krajden M; Winton T; Maurer JR
    Chest; 1993 Feb; 103(2):466-71. PubMed ID: 7679347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains.
    Alkawash M; Head M; Alshami I; Soothill JS
    J Antimicrob Chemother; 1999 Sep; 44(3):385-7. PubMed ID: 10511407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.